Publication on IL-37 and obesity

Ballak , Duby

Investigators of the department of Internal Medicine have published a paper on the role of interleukin-37 (IL-37), an anti-inflammatory member of the IL-1 family during obesity.

The paper "IL-37 protects against obesity-induced inflammation and insulin resistance" by Dov Ballak (photo), Janna van Diepen, Anneke Hijmans, Leo Joosten, Mihai Netea, Cees Tack, Charles Dinarello, Rinke Stienstra and collaborators from Wageningen, Munchen, Denver, Seoul, Be'er Sheva and Innsbruck, is published in Nature Communications.

Cytokines of the IL-1 family are important modulators of obesity-induced inflammation and the development of systemic insulin resistance. Here we show that IL-1 family member IL-37, recently characterized as an anti-inflammatory cytokine, ameliorates obesity-induced inflammation and insulin resistance. Mice transgenic for human IL-37 (IL-37tg) exhibit reduced numbers of adipose tissue macrophages, increased irculating levels of adiponectin and preserved glucose tolerance and insulin sensitivity after 16 weeks of HFD. In vitro treatment of adipocytes with recombinant IL-37 reduces adipogenesis and activates AMPK signalling. In humans, elevated steady-state IL-37 adipose tissue mRNA levels are positively correlated with insulin sensitivity and a lower inflammatory status of the adipose tissue. These findings reveal IL-37 as an important anti-inflammatory modulator during obesity-induced inflammation and insulin resistance in both mice and humans, and suggest that IL-37 is a potential target for the treatment of obesity-induced insulin resistance and type 2 diabetes.

<< back to overview news items